Skip to main content
. 2014 Jan 8;53(9):1560–1569. doi: 10.1093/rheumatology/ket414

Table 1.

Current status of investigational agentsa

Drug (mechanism) Status in RA Key ongoing trials in RA Other indications
Secukinumab (anti-IL-17A mAb) Phase 3 24-week trial in TNF-IR patients on stable MTX, with up to 2-year extension (NCT01377012); 24-week trial in TNF-IR patients on stable dose of conventional DMARD with up to 1-year extension (NCT01350804)

  • Plaque psoriasis (phase 3)

  • Psoriatic arthritis (phase 3)

  • AS (phase 3)
Ixekizumab (anti-IL-17A mAb) Phase 2 1-year extension in biologic-naive and TNF-IR patients (NCT00966875) Plaque psoriasis (phase 3)
Ustekinumab (anti-p40 mAbb) Phase 2 28-week trial in patients with active RA despite MTX vs CNTO 1959 or placebo (NCT01645280)

  • Plaque psoriasis (FDA approved)

  • Psoriatic arthritis (phase 3)

  • Crohn’s disease (phase 3)

  • Ankylosing spondylitis (phase 2)

  • Primary biliary cirrhosis (phase 2)
Tofacitinib (JAK1, 2 and 3 inhibitor) NDA filed Completed

  • Plaque psoriasis (phase 3)

  • JIA (phase 2)
Baricitinib (JAK1/2 inhibitor) Phase 2 12-week trial in patients on background MTX, with 12-week extension (NCT01185353) Plaque psoriasis (phase 2)
GLPG0634 (JAK1 inhibitor) Phase 2 4-week trial in patients refractory to MTX completed (NCT01384422); 4-week trial in patients refractory to MTX (NCT01668641) None
VX-509 (JAK3 inhibitor) Phase 2 12-week trial in patients who failed ≥1 DMARD and 0–1 biologic completed (NCT01052194); 24-week trial in patients on stable MTX (NCT01590459) None

aStatus based on information available at clinicaltrials.gov as of 13 March 2013. bBlocks IL-12 and IL-23.